Mayne launches generic Kapvay tablets
Mayne Pharma is introducing a generic version of Concordia International’s Kapvay (clonidine) extended-release tablets in a 0.1-mg dosage strength.
The product is indicated for the treatment of attention deficit hyperactivity disorder as monotherapy or as adjunct to stimulant medications.
“The launch of clonidine ER tablets is our sixth generic product launch this calendar year. This product was developed internally and will be manufactured in Greenville, N.C., leveraging our potent handling and modified-release drug delivery capabilities," said Mayne Pharma’s CEO Scott Richards.
Clonidine ER tablets had a market value of approximately $60 million for the 12 months ending April 2018, according to IQVIA data.
The product is indicated for the treatment of attention deficit hyperactivity disorder as monotherapy or as adjunct to stimulant medications.
“The launch of clonidine ER tablets is our sixth generic product launch this calendar year. This product was developed internally and will be manufactured in Greenville, N.C., leveraging our potent handling and modified-release drug delivery capabilities," said Mayne Pharma’s CEO Scott Richards.
Clonidine ER tablets had a market value of approximately $60 million for the 12 months ending April 2018, according to IQVIA data.